Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
|Articles|June 22, 2017
Applying Biologic Advances in Multiple Myeloma to Clinical Practice
Author(s)Gareth J. Morgan, MD
In this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.
Advertisement
Gareth J. Morgan, MD, of the University of Arkansas for Medical Sciences in Little Rock, Arkansas, discusses the biologic advances in multiple myeloma, and how identified mutations and pathways can offer opportunities for patients to receive targeted therapies.
Dr. Morgan gave a presentation during an education session at the 2017 ASCO Meeting entitled, "Are We Integrating Biologic Advances in Multiple Myeloma Into Clinical Practice"?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
2
Closing the Gaps in Precision Oncology for Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5